Elsubrutinib/Upadacitinib

N/A

Report date: 2025/03/26 20:01:25
NME

Base Information

Drug NameElsubrutinib/Upadacitinib
Drug Alias NameABBV-105/upadacitinib-combinationABBV 105/ABT 494ELS/UPAABBV-105/upadacitinibABBV-599
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTKTyrosine-protein kinase JAK1
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[10] 
CombinationsYes UpadacitinibElsubrutinib
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A